发布于: 雪球转发：0回复：0喜欢：0

$百济神州(06160)$ $罗氏控股(RHHBY)$

Ph III (SKYSCRAPER-01) Tecentriq + tiragolumab final OS results in 1L PD-L1+ NSCLC expected in Q1 2024；

Ph III (IMbrave152/SKYSCRAPER-14) Tecentriq + tiragolumab + Avastin in 1L HCC initiated